Spotlight on Cell and Gene Therapy: Advancing Manufacturing Towards Industry 4.0

Discover how smart bioprocessing, digital integration, and automation can help unlock the next phase of cell and gene therapy manufacturing.

As cell and gene therapies move from clinical development toward commercial-scale production, manufacturers face increasing challenges around variability, manual operations, process consistency, data integration, and manufacturing complexity.

This whitepaper explores how Industry 4.0 technologies can help CGT manufacturers build more connected, automated, and scalable manufacturing processes while improving process control, consistency, and operational efficiency.

What You’ll Learn:

• How to build a digital foundation for connected CGT manufacturing
• How advanced monitoring and analytics can improve process consistency
• How to move from manual operations toward smarter automation and control
• How integrated data can support better process understanding and decision-making
• How OpreX BioPilot connects upstream and downstream bioprocessing operations
• How no-code workflows can standardize execution and reduce process variability
• How Industry 4.0-ready platforms can support scalable, compliant CGT manufacturing